文献速递烧伤瘢痕与激光

烧伤患者的神经病理性疼痛——一个常见但文献匮乏的问题:系统综述

Neuropathic pain in burn patients - A common problem with little literature: A systematic review.
PubMed 文献 · Burns · 2024-02-28

该系统综述遵循PRISMA指南,检索PubMed、Cochrane、Embase、Scopus、Ovid和Web of Science数据库,纳入来自11个国家的文献、共4366例患者,总结烧伤患者神经病理性疼痛的发生率、管理、危险因素及治疗疗效。结果显示加巴喷丁类药物治疗效果不一,非药物治疗显示一定前景,但总体证据不足,未来需前瞻性随机研究。

要点

  • 烧伤患者神经病理性疼痛的危险因素包括高龄、酒精和药物滥用、每日吸烟、更大体表烧伤面积及更长住院时间。
  • 药物治疗以加巴喷丁/普瑞巴林为主,但各研究疗效结果不一致。
  • 非药物治疗如神经松解/重建等显示减轻疼痛强度和改善功能的潜力。

核心结论

  • 尽管神经病理性疼痛在烧伤患者伤后长期困扰多数患者,本系统综述显示关于其病理生理、结局、危险因素及各种疗法疗效的证据不足。
  • 未来评估这些因素病因学的前瞻性和随机研究可显著改善治疗策略,有望制定明确的循证方案。

研究设计与样本

  • 本系统综述按照系统综述和Meta分析优先报告条目(PRISMA)指南进行。
  • 检索数据库包括PubMed、Cochrane、Embase、Scopus、Ovid和Web of Science。
  • 纳入文章呈现来自11个不同国家的发现,涵盖4366例患者的结局。

主要发现

  • 烧伤患者神经病理性疼痛的危险因素包括高龄、酒精和药物滥用、当前每日吸烟、更大烧伤面积占总体表面积百分比(TBSA)及更长住院时间。
  • 药物治疗包括加巴喷丁/普瑞巴林(n=7)、抗坏血酸(n=1)和利多卡因(n=1),各研究关于药物治疗疗效的结果不一。
  • 某些研究显示加巴喷丁类药物有效减轻神经病理性症状,而其他研究则发现相互矛盾的结果。
  • 非药物治疗包括电休克治疗(n=1)、电针(n=1)、神经松解/重建(n=2)和躯体感觉反馈康复(n=1),显示减轻疼痛强度和改善功能的潜力。

关键数值与推荐

  • 文献报道烧伤患者神经病理性疼痛的患病率高达80%。
  • 药物治疗研究:加巴喷丁/普瑞巴林(n=7)、抗坏血酸(n=1)、利多卡因(n=1)。
  • 非药物治疗研究:电休克治疗(n=1)、电针(n=1)、神经松解/重建(n=2)、躯体感觉反馈康复(n=1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本系统综述显示关于神经病理性疼痛的病理生理、结局、危险因素及各种疗法疗效的证据不足。
  • 未来需前瞻性和随机研究评估这些因素的病因学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of neuropathic pain (NP) in burn patients is reported in the literature to be as high as 80%1. Given the complexity of NP in burn patients and the wide range of treatments available, a systematic review of the literature is warranted to summarize our current understanding of management and treatment of NP in this population. METHODS: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The following databases were queried to identify relevant articles: PubMed, Cochrane, Embase, Scopus, Ovid, and Web of Science. The main outcome measures were incidence and management of NP. Secondary outcomes included risk factors for NP. RESULTS: Included articles presented findings from 11 different countries, capturing outcomes for 4366 patients. Risk factors for neuropathic pain in burn patients were identified, including older age, alcohol and substance abuse, current daily smoking, greater % total body surface area burns (TBSA), and longer hospitalizations. Pharmacologic treatments included gabapentin/pregabalin (n = 7), ascorbic acid (n = 1), and lidocaine (n = 1). Overall, the studies showed varied results regarding the efficacy of pharmacological treatments. While certain studies demonstrated gabapentanoids to be effective in reducing neuropathic symptoms, others found conflicting results. With regards to non-pharmacologic treatments, electroconvulsive therapy (n = 1), electropuncture (n = 1), nerve release/reconstruction (n = 2), and somatosensory feedback rehabilitation (n = 1) were used and demonstrated promise in reducing pain intensity and improving functionality. CONCLUSIONS: Despite NP afflicting the majority of burn patients long after their injury, this systematic review demonstrates insufficient evidence on the pathophysiology, outcomes, and risk factors in NP, as well as the efficacy of various therapies. Future prospective and randomized studies evaluating the etiology of these factors can substantially improve our treatment strategies. This can allow for the development of well-delineated and evidence-based protocols in NP management in hopes of improving quality of life and both psychological and physical function in burn patients.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Stanton E, Won P, Manasyan A, et al. Neuropathic pain in burn patients - A common problem with little literature: A systematic review. Burns. 2024. PMID: 38472004. doi:10.1016/j.burns.2024.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。